Vanguard Group Inc. Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Vanguard Group Inc. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,570,770 shares of the company’s stock after buying an additional 25,704 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of Medpace worth $854,087,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Bank of Montreal Can raised its holdings in Medpace by 42.6% during the third quarter. Bank of Montreal Can now owns 5,874 shares of the company’s stock worth $1,947,000 after purchasing an additional 1,755 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Medpace by 1.6% in the third quarter. The Manufacturers Life Insurance Company now owns 21,469 shares of the company’s stock valued at $7,166,000 after buying an additional 340 shares in the last quarter. FMR LLC raised its stake in shares of Medpace by 11.8% during the 3rd quarter. FMR LLC now owns 231,019 shares of the company’s stock worth $77,114,000 after buying an additional 24,362 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Medpace by 92.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 79,939 shares of the company’s stock worth $26,684,000 after buying an additional 38,427 shares in the last quarter. Finally, Freedom Investment Management Inc. grew its stake in Medpace by 7.3% in the 3rd quarter. Freedom Investment Management Inc. now owns 649 shares of the company’s stock valued at $217,000 after acquiring an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 1.3 %

MEDP stock opened at $312.36 on Friday. The stock has a market capitalization of $9.52 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The stock’s fifty day simple moving average is $335.90 and its 200-day simple moving average is $339.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Leerink Partners started coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 target price for the company. Leerink Partnrs upgraded Medpace to a “hold” rating in a research report on Monday, March 24th. Finally, Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.